Pharmacokinetics of Intravenous Cyclophosphamide in Man, Estimated by Gas-liquid Chromatography

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1978 Jan 1

PMID 750109

Citations 23

Authors

F D Juma

H J Rogers

J R Trounce

I D Bradbrook

Affiliations

Soon will be listed here.

Abstract

A simple gas chromatographic assay utilising alkali flame ionisation detection is described for the estimation of cyclophosphamide as its trifluoroacetate derivative from plasma. Examination of five patients following intravenous cyclophosphamide gave values of 8.9 h (SD 2.7) for the half-life and 0.061 liters/h/kg (SD 0.011) for whole-body clearance of the drug.

Citing Articles

Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.

Diehl R, Ferrara F, Muller C, Dreyer A, McLeod D, Fricke S Cell Mol Immunol. 2016; 14(2):146-179.

PMID: 27721455 PMC: 5301156. DOI: 10.1038/cmi.2016.39.

Metabolism and pharmacokinetics of oxazaphosphorines.

Boddy A, Yule S Clin Pharmacokinet. 2000; 38(4):291-304.

PMID: 10803453 DOI: 10.2165/00003088-200038040-00001.

Ifosfamide clinical pharmacokinetics.

Wagner T Clin Pharmacokinet. 1994; 26(6):439-56.

PMID: 8070218 DOI: 10.2165/00003088-199426060-00003.

High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity.

Wright J, Elias A, Tretyakov O, Holden S, Andersen J, Wheeler C Cancer Chemother Pharmacol. 1995; 36(4):345-51.

PMID: 7628055 DOI: 10.1007/BF00689053.

The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy.

Juma F, Rogers H, Trounce J Br J Clin Pharmacol. 1980; 10(4):327-35.

PMID: 7448105 PMC: 1430090. DOI: 10.1111/j.1365-2125.1980.tb01768.x.

References

Fenselau C, Kan M, Rao S, Myles A, Friedman O, Colvin M . Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Cancer Res. 1977; 37(8 Pt 1):2538-43. View

Jardine I, Brundrett R, Colvin M, Fenselau C . Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites. Cancer Treat Rep. 1976; 60(4):403-8. View

Pantarotto C, Bossi A, Belvedere G, Martini A, Donelli M, Frigerio A . Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens. J Pharm Sci. 1974; 63(10):1554-8. DOI: 10.1002/jps.2600631014. View

Cohen J, Jao J, Jusko W . Pharmacokinetics of cyclophosphamide in man. Br J Pharmacol. 1971; 43(3):677-80. PMC: 1665783. DOI: 10.1111/j.1476-5381.1971.tb07199.x. View

Pantarotto C, Martini A, Belvedere G, Donelli M, Frigerio A . Studies on the disposition of cyclophosphamide (NSC-26271) in tumor-bearing mice by means of gas chromatography-chemical ionization-mass fragmentography. Cancer Treat Rep. 1976; 60(4):493-500. View